ALZAMEND NEURO, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ALZAMEND NEURO, INC. (ALZN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $369.38 thousand for the 3-month period ending 2023-07-31, per its 10-Q filed 2023-09-13.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2023-09-13
- ALZAMEND NEURO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-07-31 was $369.38K, a 57.41% decline year-over-year.
- ALZAMEND NEURO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2022-07-31 was $867.34K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month |
|---|---|
| 2023-07-31 | $369.38K 10-Q · filed 2023-09-13 |
| 2022-07-31 | $867.34K 10-Q · filed 2023-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |